US-REGISTERED COMPANY 
EU WAREHOUSE
Adamax and Dihexa have different research frameworks and amounts of published evidence. This comparison summarises the available preclinical findings.
Adamax: a designer analogue with limited literature
Adamax is described as a synthetic designer analogue related to Semax. However, publicly available peer-reviewed literature on its composition, pharmacology and safety is very limited. An official regulatory review from New Zealand also highlights the lack of clinical data for this group of ACTH analogues.
Medsafe: Classification of Unscheduled Peptides
Dihexa: the HGF/c-Met research framework
Dihexa is an angiotensin IV derivative studied as a modulator of HGF/c-Met signalling. Preclinical studies exist in neural and regenerative models, but these do not establish clinical efficacy or safety.
PubMed: Dihexa in a preclinical peripheral nerve repair model
| Feature | Adamax | Dihexa |
|---|---|---|
| Research framework | Designer analogue related to Semax | HGF/c-Met signalling |
| Published documentation | Very limited | Several preclinical studies |
| Key message | Effects should not be inferred from a related compound | Preclinical data do not establish clinical confirmation |
Related profiles
See Adamax, Dihexa and the neuropeptides collection.
This content is intended solely for research and educational purposes. It is not medical advice or instructions for use in humans or animals.
Related catalogue and documentation
Are Adamax and Dihexa interchangeable?
No. Different names, structures and research hypotheses do not support substituting one compound for another. Findings about Semax should not be presented as direct evidence for Adamax. Assessment requires original research on the exact compound.